

## REMARKS

### I. Introduction

It is respectfully requested that this Amendment After Final Rejection be entered and made of record. It is believed that the following amendments and remarks place the application in a form for allowance. The following amendments and remarks at least place the claims in a better form for appeal. No new matter is presented, as such the amendment is proper under 37 C.F.R. § 1.116.

Claims 1, 2, 4-9, 11-14, 16, and 33 remain in the case. Claims 19, 21-32 and 34 have been canceled.

### II. Claim Rejections - 35 U.S.C. § 112, First Paragraph

Claims 1-2, 4-9, 11-14, 16, 19, and 21-34 were rejected under 35 U.S.C. § 112, first paragraph. The Examiner states that the complex of the claims should be further limited so as to express the unique physical structure of Applicant's PVAP-PVP complex which has been prepared in the instant specification. The Examiner notes that the limitations of claims 31 and 34 express the complex structure of the claimed complex.

Applicant has now amended the claims to include the spectrum bands set forth in claims 31 and 34, now canceled. It is therefore believed that the claims now sufficiently define the unique physical structure of the PVAP-PVP complex. Applicant therefore respectfully requests that this ground of rejection be withdrawn.

### III. Claim Rejections - 35 U.S.C. § 103(a)

Claims 19, 21-30, and 32 were rejected under 35 U.S.C. § 103(a) as being obvious over Gupta et al. Drug Development and Industrial Pharmacy (1994) or M.A. Elegakey et al. P.P.S.

434-440 or Takayana Chem. Pharm. Bull. PPS 3921-4926. Applicant has now canceled claims 19, 21-30, and 32, thus rendering this ground of rejection moot.


IV. Conclusion

It is believed the application is in a prima facie condition for allowance. Allowance is respectfully requested.

No fees or extensions of time are believed to be due in connection with this amendment; however, consider this a request for any extension inadvertently omitted, and charge any additional fees to Deposit Account No. 26-0084.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,



Wendy K. Marsh, Reg. No. 39,705  
ZARLEY, McKEE, THOMTE, VOORHEES  
& SEASE  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

Attorneys of Record

- wm -

**AMENDMENT — VERSION WITH MARKINGS  
TO SHOW CHANGES MADE — DO NOT FILE**

**In the Claims**

Claims 1, 8, 19, and 21-34 were amended as follows:

1. (Twice Amended)

A polymer complex for entrapping drug granules comprising:  
a complex of polyvinyl acetate phthlate (PVAP); and  
polyvinylpyrrolidine (PVP);  
said PVAP-PVP complex having bands at about 1657 cm<sup>-1</sup> and 1724 cm<sup>-1</sup> in the spectrum of  
the PVAP-PVP complex.

7 ~~8~~ (Twice Amended)

A polymer-entrapped drug comprising:  
a drug that is insoluble in organic solvent, but soluble or suspendable in an alkaline solution and  
insoluble in aqueous acidic solutions;  
a complex of polyvinyl acetate phthlate (PVAP); and  
polyvinylpyrrolidine (PVP);  
said PVAP-PVP complex having bands at about 1657 cm<sup>-1</sup> and 1724 cm<sup>-1</sup> in the spectrum of  
the PVAP-PVP complex.

Claims 19 and 21-32 have been canceled.

1438. (Amended)

A polymer-entrapped drug comprising:  
a drug that is insoluble in organic solvent, but soluble or suspendable in an alkaline solution and  
insoluble in aqueous acidic solutions;  
said drug being entrapped in a complex of polyvinyl acetate phthlate (PVAP) and  
polyvinylpyrrolidone (PVP);  
said PVAP-PVP complex having bands at about  $1657\text{ cm}^{-1}$  and  $1724\text{ cm}^{-1}$  in the spectrum of  
the PVAP-PVP complex.

Claim 34 has been canceled.